George A. Scangos - 30 May 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
30 May 2024
Net transactions value
$0
Form type
4
Filing time
03 Jun 2024, 12:17:53 UTC
Previous filing
31 May 2024
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +8,000 +7.1% $0.000000 120,989 30 May 2024 Direct
holding VIR Common Stock 1,750,000 30 May 2024 See footnote F1
holding VIR Common Stock 1,750,000 30 May 2024 See footnote F2
holding VIR Common Stock 33,629 30 May 2024 See footnote F3
holding VIR Common Stock 179,930 30 May 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +16,000 $0.000000 16,000 30 May 2024 Common Stock 16,000 $10.39 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F2 The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F3 The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F4 The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.